Drugs Procurement Tender DRUG REVIEW COMMITTEE Medicines Supply 2026 - Drug License, PBG 5%, Shelf Life 5/6

Tender Overview

The opportunity involves supplying medicines to a government body managed by the DRUG REVIEW COMMITTEE. Bidders must provide samples for quality review and demonstrate a valid drug license. For supplies exceeding ₹5,00,000, a Performance Bank Guarantee (PBG) of 5% is required in both hard and soft copies. The contract emphasizes shelf life integrity, requiring medicines to maintain a 5/6 shelf life at delivery and a two-month expiry exchange window for near-expiry stock. The BOQ lists no items, indicating a needs-based or future-award process and potential scope pending review. This tender targets approved pharmaceutical suppliers with quality assurances and compliant documentation.

Technical Specifications & Requirements

• Sample submission: drugs delivered for DRUG REVIEW COMMITTEE evaluation prior to bid opening
• PBG: 5% for supply orders above ₹5,00,000; provide both hard and soft copy
• Licensing: must hold a valid drug license authorizing sale of medicines
• Shelf life: all medicines must retain a minimum 5/6 shelf life at delivery
• Expiry exchange: suppliers must exchange expiring or near-expiry medicines two months before expiry
• No BOQ items listed; scope may be defined during bid review and sample assessment
• Focus on vendors with quality control and drug quality assurance capabilities

Terms, Conditions & Eligibility

• EMD/guarantees: not specified in data; bidders should prepare standard bid security as per terms
• Compliance: adhere to drug licensing and quality review procedures
• Quality controls: samples reviewed by DRUG REVIEW COMMITTEE; non-compliance leads to disqualification
• Delivery/Exchanges: two-month near-expiry exchange policy; ensure stock meets shelf life requirements
• Bid review process: only compliant vendors with sample Quality Review pass to next stage
• Documentation: maintain license proofs, sample records, and PBG receipts for submission